← Contineum Therapeutics, Inc. (CTNM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Contineum Therapeutics, Inc. (CTNM)
Pharmaceutical Preparations · market cap $304M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Contineum Therapeutics (CTNM) is a clinical-stage pharmaceutical company with 41 employees and a ~$362M market cap, running three Phase 2 programs: PIPE-791 (Idiopathic Pulmonary Fibrosis), PIPE-505 (Sensorineural Hearing Loss), and PIPE-307 (Relapsing Remitting MS). The company holds only $20.2M in cash, implying a runway of approximately 3.7 months, making near-term financing a near-certainty and a dominant risk.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PIPE-791 Dose A | Phase 2 | Idiopathic Pulmonary Fibrosis |
| PIPE-505 | Phase 2 | Sensorineural Hearing Loss |
| PIPE-307 Dose A | Phase 2 | Relapsing Remitting Multiple Sclerosis |
Price & technical context
3-month
-11.9%
6-month
+2.8%
12-month
+13.5%
52-wk range
$9.17–$17.57
vs 50-day MA
-10.2%
vs 200-day MA
-2.0%
Realized vol
67.9%
Max drawdown
-83.1%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CTNM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.